ArticleThe British journal of dermatology2021
Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study.
Article in The British journal of dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Role of real-world evidence from patient registries for psoriasis in decision-making: a systematic review.BMJ open quality · 2026Pooled it
- A systematic review of sex and gender differences in treatment outcome of inflammatory skin diseases: Is it time for new guidelines?Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis: A Meta-analysis.JAMA dermatology · 2024Pooled it
- Article
- Sex hormone-psoriasis interactions: from sex-specific clinical features to immunoregulatory mechanisms.Frontiers in immunology · 2026Review
- Relative Efficacy of Immunomodulatory Monotherapies for Psoriasis of the Scalp: A Network Meta-Analysis Study.Journal of cosmetic dermatology · 2026Article
- Development and validation of a prediction model for primary non-response to IL-17A inhibitors in psoriasis.Frontiers in medicine · 2026Article
- Comparing the effectiveness and drug persistence of methotrexate, cyclosporine, and acitretin for psoriasis.International journal of women's dermatology · 2025Article
- Comparative Effectiveness and Durability of Biologics Through 24 Months for Patients with Moderate-to-Severe Psoriasis: Results from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).Dermatology and therapy · 2025Article
- Effectiveness and Safety of Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis in Real-World Practice in Korea: A Prospective, Multicenter, Observational, Postmarketing Surveillance Study.The Journal of dermatology · 2025Observational
- Sex Disparities of Health-related Quality of Life in Moderate to Severe Psoriasis: A Real-world Analysis from the Swiss Psoriasis Registry (SDNTT).Acta dermato-venereologica · 2025Article
- Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months.Dermatology and therapy · 2025Article
- Dimethyl Fumarate Treatment for Psoriasis in Real-World Clinical Practice: An Analysis from the Swiss Registry.Dermatology (Basel, Switzerland) · 2025Article
- Sex Differences in Dermatology Life Quality Index (DLQI) among Patients with Psoriasis.Acta dermato-venereologica · 2024Article
- Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT).Acta dermato-venereologica · 2024Observational
- Psoriasis localization patterns in the Swiss Psoriasis Registry (SDNTT) over 11 years: an analysis by sex and age.Archives of dermatological research · 2024Article
- Predicting Psoriatic Arthritis in Psoriasis Patients - A Swiss Registry Study.Journal of psoriasis and psoriatic arthritis · 2024Article
- Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis.Acta dermato-venereologica · 2024Article
- A novel online calculator based on clinical features and hematological parameters to predict total skin clearance in patients with moderate to severe psoriasis.Journal of translational medicine · 2024Article
- Retrospective pharmacogenetic study of psoriasis highlights the role of KLK7 in tumour necrosis factor signalling.The British journal of dermatology · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFew systematic data on sex-related treatment responses exist for psoriasis.
objectivesTo evaluate sex differences with respect to systemic antipsoriatic treatment.
methodsData from patients with moderate-to-severe psoriasis in the PsoBest or Swiss Dermatology Network of Targeted Therapies (SDNTT) registries were analysed. Treatment response was defined as achieving a ≥ 75% reduction in Psoriasis Area and Severity Index (PASI 75) or PASI ≤ 3 at treatment months 3, 6 and 12, supplemented by patient-reported outcomes [i.e. Dermatology Life Quality Index (DLQI) ≤ 1 and delta DLQI ≥ 4].
resultsIn total, 5346 patients registered between 2007 and 2016 were included (PsoBest, n = 4896; SDNTT, n = 450). The majority received nonbiological treatment (67·3% male, 69·8% female). Women showed slightly higher PASI response rates after 3 (54·8% vs. 47·2%; P ≤ 0·001), 6 (70·8% vs. 63·8%; P ≤ 0·001) and 12 months (72·3% vs. 66·1%; P ≤ 0·004). A significantly higher proportion of women achieved a reduction in DLQI ≥ 4 [month 3: 61·4% vs 54·8% (P ≤ 0·001); month 6: 69·6% vs. 62·4% (P ≤ 0·001); month 12: 70·7% vs. 64·4% (P ≤ 0·002)]. Regarding PASI ≤ 3, women on biologics showed a significantly superior treatment response compared with men at 3 (57·8% vs. 48·5%; P ≤ 0·004) and 6 months (69·2% vs. 60·9%; P ≤ 0·018). Women in the nonbiological treatment group had a significantly better treatment response (PASI response, PASI 75 and PASI ≤ 3) over 12 months compared with men.
conclusionsWe provide evidence that women experience better treatment outcomes with systemic antipsoriatic therapy than men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.